| Patent Number |
Title Of Patent |
Date Issued |
| 6506883 |
Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EG |
January 14, 2003 |
| Humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The humanized and monoclonal antibodies may comprise variable regions of non-human origin and constant |
| 6491914 |
Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, |
December 10, 2002 |
| An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-Id monoclonal antibody of the pre |
| 6149921 |
Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and thei |
November 21, 2000 |
| The invention provides novel uses for n-glycolylated gangliosides and N-acetylated gangliosides, or derivatives and/or oligosaccharides thereof The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gan |
| 6063379 |
Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal an |
May 16, 2000 |
| An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-idiotype monoclonal antibody of t |
| 5891996 |
Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EG |
April 6, 1999 |
| New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: light |
| 5817513 |
Anti ganglioside monoclonal antibodies |
October 6, 1998 |
| The present invention relates to immunotherapy strategies for the treatment of malignancies. The present immunotherapy strategies have gangliosides as a target. Gangliosides are glycosphingolipids which are present on normal cells and on malignant cells. On malignant cells they are more |
| 5788985 |
Vaccine composition for eliciting an immune response against N-glycolylated gangliosides and its |
August 4, 1998 |
| The invention provides novel uses for n-glycolylated gangliosides, or derivatives and/or oligosaccharides thereof. The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to c |
